Adverse Features News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Adverse Features. Real-time updates on events, politics, business and more.

Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones

September 21, 2022

On track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022 Overall survival data from the Actimab-A CLAG-M combination trial...

United States Hans Vitzthum Sandesh Seth Actinium Technology Platform Lifesci Advisors Alpha Therapy Program

Source: prnewswire.com

Actinium Announces Multiple Abstracts Highlighting Iomab-B and Actimab-A Accepted for Presentation at the 63rd Annual American Society of Hematology Annual Meeting

November 4, 2021

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies for...

United States Georgia World Congress Center Sandesh Seth Hans Vitzthum Lifesci Advisors American Society Of Hematology

Source: prnewswire.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation

Adverse Features News Today

Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones

Actinium Announces Multiple Abstracts Highlighting Iomab-B and Actimab-A Accepted for Presentation at the 63rd Annual American Society of Hematology Annual Meeting

Explore More Categories